Clinical Trial Update: Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients [Phase 3]

View source ↗

Summary

Phase 3 trial update on everolimus (Certican) in pediatric de novo kidney transplant patients, reporting safety and efficacy results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Certican (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Kidney Transplantation | Phase 3 | Status: COMPLETED